Please wait while the formulary information is being retrieved.
Drug overview for TRIESENCE (triamcinolone acetonide/pf):
Generic name: TRIAMCINOLONE ACETONIDE/PF
Drug class: Ophthalmic Steroids
Therapeutic class: Ophthalmic Agents
Triamcinolone acetonide is a synthetic corticosteroid.
No enhanced Uses information available for this drug.
Generic name: TRIAMCINOLONE ACETONIDE/PF
Drug class: Ophthalmic Steroids
Therapeutic class: Ophthalmic Agents
Triamcinolone acetonide is a synthetic corticosteroid.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for TRIESENCE (triamcinolone acetonide/pf) have been approved by the FDA:
Indications:
Giant cell arteritis
Ophthalmia sympathetic
Severe ocular inflammation
Uveitis
Vitrectomy adjunct to enhance visualization
Professional Synonyms:
Cranial arteritis
Extracranial arteritis
Giant-cell arteritis
Granulomatous arteritis
Horton's arteritis
Severe ophthalmic inflammation
Sympathetic ophthalmia
Temporal arteritis
Indications:
Giant cell arteritis
Ophthalmia sympathetic
Severe ocular inflammation
Uveitis
Vitrectomy adjunct to enhance visualization
Professional Synonyms:
Cranial arteritis
Extracranial arteritis
Giant-cell arteritis
Granulomatous arteritis
Horton's arteritis
Severe ophthalmic inflammation
Sympathetic ophthalmia
Temporal arteritis
The following dosing information is available for TRIESENCE (triamcinolone acetonide/pf):
The nasal aqueous suspension spray pump delivers about 55 mcg of triamcinolone acetonide per metered spray.
Triamcinolone acetonide is administered by nasal inhalation as an aqueous suspension using a spray pump. Patients should be carefully instructed in the use of the nasal inhalation spray pump, including the need to prime the pump prior to first use and after a period of nonuse (i.e., 2 weeks or more). Prior to administration of the nasal suspension, patients should be instructed to shake the container well.
Patients should gently blow the nose to clear their nasal passages. Patients should tilt the head slightly backward and insert the spray tip into one nostril, pointing the tip toward the back of the nose. The drug suspension should be sprayed into one nostril while holding the other nostril closed and concurrently inspiring through the nose.
This procedure should be repeated for the other nostril. Patients should avoid blowing the nose for 15 minutes after inhalation.
Patients should gently blow the nose to clear their nasal passages. Patients should tilt the head slightly backward and insert the spray tip into one nostril, pointing the tip toward the back of the nose. The drug suspension should be sprayed into one nostril while holding the other nostril closed and concurrently inspiring through the nose.
This procedure should be repeated for the other nostril. Patients should avoid blowing the nose for 15 minutes after inhalation.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for TRIESENCE (triamcinolone acetonide/pf):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for TRIESENCE (triamcinolone acetonide/pf):
Drug contraindication overview.
Known hypersensitivity to triamcinolone acetonide or any ingredient in the respective formulations.
Known hypersensitivity to triamcinolone acetonide or any ingredient in the respective formulations.
There are 6 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Cerebral malaria |
| Fungal infection of eye |
| Herpes zoster keratitis |
| Herpes zoster keratoconjunctivitis |
| Ocular herpes simplex |
| Tuberculosis of the eye |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Cataracts |
| Ocular hypertension |
| Viral ocular infection |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Diabetes mellitus |
| Glaucoma |
The following adverse reaction information is available for TRIESENCE (triamcinolone acetonide/pf):
Adverse reaction overview.
Adverse effects occurring in at least 2% of adults and children 12 years of age or older receiving triamcinolone acetonide nasal aqueous suspension in clinical trials and more frequently than with placebo included pharyngitis, epistaxis, and increased cough. Adverse effects occurring in more than 2% of children 4-12 years of age receiving triamcinolone acetonide nasal aqueous suspension in clinical trials and more frequently than with placebo included flu syndrome, increased cough, pharyngitis, bronchitis, dyspepsia, and tooth disorder. Adverse effects occurring in at least 2% of children 2-5 years of age receiving triamcinolone acetonide nasal aqueous suspension in one study and more frequently than with placebo included headache, pharyngolaryngeal pain, epistaxis, nasopharyngitis, upper abdominal pain, diarrhea, asthma, rash, excoriation, and rhinorrhea.
Adverse effects occurring in at least 2% of adults and children 12 years of age or older receiving triamcinolone acetonide nasal aqueous suspension in clinical trials and more frequently than with placebo included pharyngitis, epistaxis, and increased cough. Adverse effects occurring in more than 2% of children 4-12 years of age receiving triamcinolone acetonide nasal aqueous suspension in clinical trials and more frequently than with placebo included flu syndrome, increased cough, pharyngitis, bronchitis, dyspepsia, and tooth disorder. Adverse effects occurring in at least 2% of children 2-5 years of age receiving triamcinolone acetonide nasal aqueous suspension in one study and more frequently than with placebo included headache, pharyngolaryngeal pain, epistaxis, nasopharyngitis, upper abdominal pain, diarrhea, asthma, rash, excoriation, and rhinorrhea.
There are 20 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Cataracts |
Endophthalmitis Glaucoma Infection Ocular infection |
| Rare/Very Rare |
|---|
|
Allergic dermatitis Conjunctival hemorrhage Depression Diabetes mellitus Drug-induced psychosis Gastrointestinal hemorrhage Hypercortisolism Hypokalemia Hypopyon Hypothalamic-pituitary insufficiency Myopathy Osteoporosis Peptic ulcer Retinal detachment Skin rash |
There are 15 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Ocular hypertension |
Blurred vision Increased appetite Ocular discomfort |
| Rare/Very Rare |
|---|
|
Euphoria Gastric acid hypersecretory conditions Hirsutism Insomnia Irregular menstrual periods Mood changes Ocular inflammation Personality disorders Reduced visual acuity Skin hypopigmentation Vitreous floater |
The following precautions are available for TRIESENCE (triamcinolone acetonide/pf):
Safety and efficacy of intranasal triamcinolone acetonide suspension have not been established in children younger than 2 years of age. Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy; these infants should be monitored carefully.
Not known whether triamcinolone acetonide is distributed into milk. Caution is advised if the drug is administered in nursing women.
Experience from clinical trials in those 65 years of age or older is insufficient to determine whether they respond differently from younger adults. Based on other reported clinical experience to date, no substantial differences in safety and efficacy relative to younger adults is apparent.
The following prioritized warning is available for TRIESENCE (triamcinolone acetonide/pf):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for TRIESENCE (triamcinolone acetonide/pf)'s list of indications:
| Giant cell arteritis | |
| M31.5 | Giant cell arteritis with polymyalgia rheumatica |
| M31.6 | Other giant cell arteritis |
| Ophthalmia sympathetic | |
| H44.13 | Sympathetic uveitis |
| H44.131 | Sympathetic uveitis, right eye |
| H44.132 | Sympathetic uveitis, left eye |
| H44.133 | Sympathetic uveitis, bilateral |
| H44.139 | Sympathetic uveitis, unspecified eye |
| Severe ocular inflammation | |
| H57.8 | Other specified disorders of eye and adnexa |
| H57.89 | Other specified disorders of eye and adnexa |
| Uveitis | |
| D86.83 | Sarcoid iridocyclitis |
| H20 | Iridocyclitis |
| H20.0 | Acute and subacute iridocyclitis |
| H20.00 | Unspecified acute and subacute iridocyclitis |
| H20.01 | Primary iridocyclitis |
| H20.011 | Primary iridocyclitis, right eye |
| H20.012 | Primary iridocyclitis, left eye |
| H20.013 | Primary iridocyclitis, bilateral |
| H20.019 | Primary iridocyclitis, unspecified eye |
| H20.02 | Recurrent acute iridocyclitis |
| H20.021 | Recurrent acute iridocyclitis, right eye |
| H20.022 | Recurrent acute iridocyclitis, left eye |
| H20.023 | Recurrent acute iridocyclitis, bilateral |
| H20.029 | Recurrent acute iridocyclitis, unspecified eye |
| H20.03 | Secondary infectious iridocyclitis |
| H20.031 | Secondary infectious iridocyclitis, right eye |
| H20.032 | Secondary infectious iridocyclitis, left eye |
| H20.033 | Secondary infectious iridocyclitis, bilateral |
| H20.039 | Secondary infectious iridocyclitis, unspecified eye |
| H20.04 | Secondary noninfectious iridocyclitis |
| H20.041 | Secondary noninfectious iridocyclitis, right eye |
| H20.042 | Secondary noninfectious iridocyclitis, left eye |
| H20.043 | Secondary noninfectious iridocyclitis, bilateral |
| H20.049 | Secondary noninfectious iridocyclitis, unspecified eye |
| H20.1 | Chronic iridocyclitis |
| H20.10 | Chronic iridocyclitis, unspecified eye |
| H20.11 | Chronic iridocyclitis, right eye |
| H20.12 | Chronic iridocyclitis, left eye |
| H20.13 | Chronic iridocyclitis, bilateral |
| H20.2 | Lens-induced iridocyclitis |
| H20.20 | Lens-induced iridocyclitis, unspecified eye |
| H20.21 | Lens-induced iridocyclitis, right eye |
| H20.22 | Lens-induced iridocyclitis, left eye |
| H20.23 | Lens-induced iridocyclitis, bilateral |
| H20.8 | Other iridocyclitis |
| H20.81 | Fuchs' heterochromic cyclitis |
| H20.811 | Fuchs' heterochromic cyclitis, right eye |
| H20.812 | Fuchs' heterochromic cyclitis, left eye |
| H20.813 | Fuchs' heterochromic cyclitis, bilateral |
| H20.819 | Fuchs' heterochromic cyclitis, unspecified eye |
| H20.9 | Unspecified iridocyclitis |
| H44.11 | Panuveitis |
| H44.111 | Panuveitis, right eye |
| H44.112 | Panuveitis, left eye |
| H44.113 | Panuveitis, bilateral |
| H44.119 | Panuveitis, unspecified eye |
| H44.13 | Sympathetic uveitis |
| H44.131 | Sympathetic uveitis, right eye |
| H44.132 | Sympathetic uveitis, left eye |
| H44.133 | Sympathetic uveitis, bilateral |
| H44.139 | Sympathetic uveitis, unspecified eye |
Formulary Reference Tool